Correlation of expression of aberrant immunophenotypic markers in T-ALL with its morphology: A pilot study

ABSTRACT

INTRODUCTION: Aberrant expression of immunophenotypic markers is commonly found in patients of acute leukemia. T-ALL also shows aberrant markers such as CD13, CD33, CD117, CD10, and CD79a. Morphologically, T-ALL has been categorized into L1, L2, and L3 subtypes. Till now, no study has been done to correlate these markers with morphological features of T-ALL. This study aimed to correlate the expression of aberrant immunophenotypic markers with morphology in T-ALL.

MATERIALS AND METHODS: All the cases of T-ALL diagnosed by flow cytometry over a period of 2½ year were taken out from the records of Hematology Section of Department of Pathology of University College of Medical Science and Guru Teg Bahadur Hospital and Max Hospital, Saket. Their peripheral blood smear was screened to correlate the morphology of blasts with the expression of aberrant markers.

RESULTS: A total of 40 cases of T-ALL were identified during 2½ year period of our study. Morphological correlation was available for 23 cases. Aberrant expression of CD10 was present in 6 (35.3%) cases, CD79a in 9 (47.36%) cases, CD117 in 5 (42.28%) cases and myeloid antigen CD33 in 5 (38.46%) cases. CD117 and CD33-positive cases showed L2 morphology with the presence of convolutions, while cases with expression of CD79a had L1 morphology with absent-slight convolutions. CD10-positive cases had L1/L2 morphology with absent occasionally present convolutions.

CONCLUSION: There seems to be an association of aberrant markers with L1 and L2 morphology. However, this needs to be tested for statistical significance on a larger sample size.

Keywords

Acute lymphoblastic leukemias - lymphoid cell neoplasms - neoplasia - T cell neoplasms

Publication History

Received: 04 March 2018

Accepted: 05 August 2018

Article published online:
20 February 2020

• 1 Amin MM, Kermani S, Talebi A, Oghli MG. Recognition of acute lymphoblastic leukemia cells in microscopic images using k-means clustering and support vector machine classifier. J Med Signals Sens 2015;5:49-58.
• 2 Borowitz MJ, Falletta JM. Leukemias and lymphomas of thymic differentiation. Clin Lab Med 1988;8:119-34.
• 3 Ahmadzadeh A, Saedi S, Jaseb K, Asnafi AA, Alghasi A, Saki N, et al. T-cell acute lymphoblastic leukemia with del (7) (q11.2q22) and aberrant expression of myeloid markers. Int J Hematol Oncol Stem Cell Res 2013;7:40-4.
• 4 Pui CH, Rivera GK, Hancock ML, Raimondi SC, Sandlund JT, Mahmoud HH, et al. Clinical significance of CD10 expression in childhood acute lymphoblastic leukemia. Leukemia 1993;7:35-40.
• 5 Lai R, Juco J, Lee SF, Nahirniak S, Etches WS. Flow cytometric detection of CD79a expression in T-cell acute lymphoblastic leukemias. Am J Clin Pathol 2000;113:823-30.
• 6 Bhushan B, Chauhan PS, Saluja S, Verma S, Mishra AK, Siddiqui S, et al. Aberrant phenotypes in childhood and adult acute leukemia and its association with adverse prognostic factors and clinical outcome. Clin Exp Med 2010;10:33-40.
• 7 Hoehn D, Medeiros LJ, Chen SS, Tian T, Jorgensen JL, Ahmed Y, et al. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Am J Clin Pathol 2012;137:213-9.
• 8 Paietta E, Ferrando AA, Neuberg D, Bennett JM, Racevskis J, Lazarus H, et al. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood 2004;104:558-60.
• 9 Pilozzi E, Müller-Hermelink HK, Falini B, de Wolf-Peeters C, Fidler C, Gatter K, et al. Gene rearrangements in T-cell lymphoblastic lymphoma. J Pathol 1999;188:267-70.
• 10 Consolini R, Legitimo A, Rondelli R, Guguelmi C, Barisone E, Lippi A, et al. Clinical relevance of CD10 expression in childhood ALL. The Italian association for pediatric hematology and oncology (AIEOP). Haematologica 1998;83:967-73.